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50 Poster Session-I(A,B,C) and 56 different class II (DR,DQ,DP) alleles on a Luminex
platform (One Lambda, Canoga Park, CA) to determine antibody
production in both the GVH and HVG directions. Since the thresh-
old Ab response to HLA MM in marrow transplantation is unknown,
we applied the established scale from solid organ transplantation
where $1000 is positive, 500–999 is possible, and\500 is negative.
The limitation of the analysis is that the beads contain every antigen
but not every allele. In the 40 pairs, no anti-A, B, or C allele-specific
antibodies were detected at day 100 in either direction. Results for
class II antibody are shown in the table below. There is evidence
for class II allele-specific antibody production to the MM allele in
both the GVH and HVG directions with the highest frequency Ab
seen against DPA1. In conclusion, day 100 Ab to class II rather
than class I allele MM are observed in this pilot study. This may re-
flect greater immunogenicity of class II as compared to class I, a long-
standing observation in transplantation. Current studies to
determine if these are de novo or preformed Ab are being performed
using pretransplant sera from these same pairs. Future studies will
look at Ab association with GVHD and disease relapse with attention
to class II on B cells as a meaningful GVL target.
Class II Antibody Analysis
DRB1 DQB1 DQA1 DPB1 DPA1# of GVH
disparate alleles8 13 8 46 14Allele Ab test
available3 7 5 13 11Frequency of
Ab$ 10000 0 0 2/13 (15%) 2/11 (18%)Frequency of
Ab$5002/3 (67%) 2/7 (29%) 0 4/13 (31%) 6/11 (55%)# of HVG
disparate alleles8 13 9 44 13Allele Ab test
available1 2 6 17 10Frequency of
Ab$10000 0 0 0 2/10 (20%)Frequency of
Ab$5001/1 (100%) 0 0 5/17 (29%) 7/10 (70%)GVH5graft-versus-host; HVG5host-versus-graft.129
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There is an unresolved question whether unmanipulated matched
unrelated donor (MUD) PBSCT leads to a worse overall outcome
and higher incidence of severe GvHD in comparison with well estab-
lished MUD-BMT. It is well known that PBSC grafts contain ca 1
log more mature T cells, which may result in higher rate of severe
and often fatal acute/chronic GvHD after MUD-PBSCT. The aim
of our study was to compare the results of MUD-PBSCT vs
MUD-BMT in a large mostly pediatric patient population. We an-
alyzed the records of 177 consecutive pts (with hematologic malig-
nancies, n 5 148 and non-malignant disorders, n 5 29), who
underwent MUD-BMT (42 pts) or MUD-PBSCT (135 pts) between
1999 and February 2008 in our department. Probability of overall
survival for all pts after MUD-PBSCT was 0.54 and after
MUD-BMT was 0.46 (p 5 NS). Median follow-up of surviving 97
pts (55%) was 3 years. Furthermore, there was no difference between
the probability of incidence of both acute GvHD grade III-IV be-
tween the recipients of MUD-PBSCT (0.2) or MUD-BMT (0.25)
and extensive chronic GvHD (0.21 for MUD-PBSCT recipients
and 0.18 for MUD-BMT recipients). With regard to ‘‘high resolu-tion’’ HLA match, 84 donor-recipient pairs were fully matched,
whereas 64 were mismatched at one, 24 at two and 5 at three loci.
Probability of survival, acute GvHD grades III-IV and extensive
cGvHD were for respective groups as follows: 0.53, 0.18, 0.17 for
10 of 10 allele matched group, 0.47, 0.21, 0.18 for 9 of 10 allele
matched group and surprisingly 0.58, 0.27 and 0.27 for 8 of 10 allele
matched group. In the latter group, however, if two HLA antigens
were mismatched the probability of survival decreased to 0.38, prob-
ability of severe aGvHD increased to 0.46 and of extensive cGvHD
to 0.6. If only one antigen 1 one allele or two alleles were mis-
matched, the probability of survival was as high as 0.65 and probabil-
ity of severe aGvHD as low as 0.19. In conclusion, the results of
MUD-PBSCT in a large prospective cohort of pts are similar if
not better than the results of MUD-BMT. There seems to be no in-
creased risk of severe GvHD after MUD-PBSCT. MUD-PBSCT
might offer a better disease control in patients with malignancies, es-
pecially with AML. With regard to the degree of HLA match it
seems that transplants from 8 of 10 allele matched donors (with max-
imum 1 mismatched antigen) influence neither survival nor inci-
dence of severe GvHD, whereas one should avoid performing
transplants from two antigen mismatched donors.130
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Objectives: To investigate relevant factors affecting the outcome
of reduced-intensity cord blood transplantation (RI-CBT), we ana-
lyzed retrospectively the results of 128 adult patients with acute
myeloid leukemia (AML)/ myelodysplastic syndrome (MDS) in Tor-
anomon hospital.
Patients and Methods: We reviewed medical records of 128
patients with AML/MDS who had received RI-CBT between
Feburuary 2002 and July 2007 at Toranomon Hospital, Tokyo,
Japan. The following factors were considered as potential predictors
of outcomes: patient’s age, ECOG performance status (PS), HLA
disparity, infused Total nucleated cell (TNC) dose/CD34 dose, dis-
ease/disease status, cytogenetics (SWOG/ECOG criteria) at UCBT,
acute graft versus host disease (GvHD) and chronic GvHD. All fac-
tors were tested for the proportional hazards assumption. Time to
event curves were plotted by using the actuarial method of Kaplan-
Meier and differences between curves were analyzed by log-rank
tests.
Results: Patient’s median age was 58 years (17–82). Diagnoses in-
clude de novo AML (n5 68), MDS overt AML (n5 35), refractory
anemia (RA) (n 5 10), and refractory anemia with excess of blasts
(RAEB) (n 5 14). Eighty patients, who were at PS 0 or 1, and 47
patients were PS 2 or more. Disease status consisted of standard
(n 5 17) and advanced (n 5 110). HLA disparities were 4/6 match
(n 5 83), 5/6 (n 5 39), and 6/6 (n 5 5). TNC/CD34 cell dose
were 2.510E7/kg (1.8–4.5) and 0.710E5/kg (0.1 – 2.0), respec-
tively. Main conditioning regimen was Fludarabine (125mg/m2)
1Melphalan (80mg/m2) 1TBI 4Gy. GvHD prophylaxis consisted
of tacrolimus (Tac) alone in 68, Tac plus mycophenolate mofetil
in 24, and cyclosporine alone in 35. All patient received single cord
blood unit. Neutrophil engraftment was achieved in 86% (median
21 days). Incidence of grade II-IV acute GvHD and chronic
GvHD were 40 and 22%, respectively. Transplantation -related
mortality (TRM) at 2-years was 48% (95% CI 37–58). Estimated
3-years Leukemia free survival (LFS) was 25% (95% CI 16–36)
and (standard risk 64% (95% CI 48–87) and high risk 17% (95%
CI 6–27)). In univariate analysis, variables associated with improved
survival were standard risk (P5 0.02) and PS 0–1 (p\0.001), while
other factors were not significant.
Discussion/Conclusion: We conclude that RI-CBT is a viable
therapeutic option for adult AML/MDS patients. Higher TRM
was the biggest problem to be solved to increase the feasibility of
this approach.
